CFO
CALT

CVA Family Office’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

CVA Family Office’s Portfolio CALT Stock Details CALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-45
Closed -$945 – 1306
2024
Q1 		$945 Buy
+45
New +$1K ﹤0.01% 1006

Other funds holding CALT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
IIM
Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCMC
Planning Capital Management Corporation Paoli, Pennsylvania $151M AUM 30.62% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CVA Family Office's CALT Position: Q2 2024 in Review

CVA Family Office sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q2 2024, closing a stake of 45 shares — an estimated $945 sold.

CVA Family Office first reported a position in CALT in Q1 2024 and held it in 1 quarter. The position peaked at $945 in Q1 2024. 18 funds tracked by Wall St. Rank hold CALT as of Q2 2024.

  • CVA Family Office reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q2 2024 after selling out during the quarter.
  • CVA Family Office sold 45 Calliditas Therapeutics AB American Depositary Shares shares in Q2 2024, an estimated $945.
  • CVA Family Office first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q1 2024 and held it in 1 quarter.
  • CVA Family Office's Calliditas Therapeutics AB American Depositary Shares position peaked at $945 in Q1 2024.
  • 18 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q2 2024.

Based on CVA Family Office's 13F filing for Q2 2024, filed 10 Jul 2024.